TaiMed Biologics (4147.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Taiwan · ISIN TW0004147004

Price
61.00 TWD
Market cap
16.67 bn TWD
P/E (2025)
–
P/S (2025)
27.26
Dividend yield
0.00 %
Net margin
-27.44 %
Return on equity (ROE)
-4.35 %
Return on assets (ROA)
-3.49 %

TaiMed Biologics financials

Fiscal year20242025
Revenue610.16 m TWD611.35 m TWD
Gross profit211.23 m TWD259.45 m TWD
Operating income-252.27 m TWD-194.65 m TWD
EBIT-189.23 m TWD-157.06 m TWD
Net income-201.83 m TWD-167.78 m TWD
Diluted EPS – continuing operations-0.74 TWD-0.61 TWD

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About TaiMed Biologics

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates for cancer treatment. In addition, the company offers contract development and manufacturing services. It has a research and development agreement with Genentech and Biogen Inc. for Trogarzo TMB-355; and authorizes Samsung Biologics to produce TMB-355. TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.